In this context, it is interesting to mention that one of the vaccines reaching this threshold was the TriMixDC-vaccine, consisting of monocyte-derived DCs electroporated with TAA mRNA in combination with three mRNA molecules encoding CD40 Ligand (CD40L), constitutively active Toll-like receptor (TLR) 4 (caTLR4) and CD70, highlighting that mRNA is an interesting cancer vaccine technology platform allowing the transfer of tumor antigens to DCs in combination with proteins that endow the DCs with strong T cell stimulatory capacity [125]. The gene discussed is CD40LG; the disease is neoplasm.